These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35163005)

  • 21. Network-based Biased Tree Ensembles (NetBiTE) for Drug Sensitivity Prediction and Drug Sensitivity Biomarker Identification in Cancer.
    Oskooei A; Manica M; Mathis R; Martínez MR
    Sci Rep; 2019 Nov; 9(1):15918. PubMed ID: 31685861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PredictiveNetwork: predictive gene network estimation with application to gastric cancer drug response-predictive network analysis.
    Park H; Imoto S; Miyano S
    BMC Bioinformatics; 2022 Aug; 23(1):342. PubMed ID: 35974335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: a targeted approach for pathway analysis.
    Lang WH; Sandoval JA
    J Biomol Screen; 2014 Oct; 19(9):1235-45. PubMed ID: 25092063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
    Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
    Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
    O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
    Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two-step multi-omics modelling of drug sensitivity in cancer cell lines to identify driving mechanisms.
    Kusch N; Schuppert A
    PLoS One; 2020; 15(11):e0238961. PubMed ID: 33226984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized Network Modeling of the Pan-Cancer Patient and Cell Line Interactome.
    Bhattacharyya R; Ha MJ; Liu Q; Akbani R; Liang H; Baladandayuthapani V
    JCO Clin Cancer Inform; 2020 May; 4():399-411. PubMed ID: 32374631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DIFFERENTIAL PATHWAY DEPENDENCY DISCOVERY ASSOCIATED WITH DRUG RESPONSE ACROSS CANCER CELL LINES.
    Speyer G; Mahendra D; Tran HJ; Kiefer J; Schreiber SL; Clemons PA; Dhruv H; Berens M; Kim S
    Pac Symp Biocomput; 2017; 22():497-508. PubMed ID: 27897001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating Domain Specific Knowledge and Network Analysis to Predict Drug Sensitivity of Cancer Cell Lines.
    Kim S; Sundaresan V; Zhou L; Kahveci T
    PLoS One; 2016; 11(9):e0162173. PubMed ID: 27607242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive Mutational and Phenotypic Characterization of New Metastatic Cutaneous Squamous Cell Carcinoma Cell Lines Reveal Novel Drug Susceptibilities.
    Perry J; Ashford B; Thind AS; Gauthier ME; Minaei E; Major G; Iyer NG; Gupta R; Clark J; Ranson M
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo.
    Su Y; Li X; Ma J; Zhao J; Liu S; Wang G; Edwards H; Taub JW; Lin H; Ge Y
    Biochem Pharmacol; 2018 Feb; 148():13-26. PubMed ID: 29208365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Network-based drug sensitivity prediction.
    Ahmed KT; Park S; Jiang Q; Yeu Y; Hwang T; Zhang W
    BMC Med Genomics; 2020 Dec; 13(Suppl 11):193. PubMed ID: 33371891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterizing Cancer Drug Response and Biological Correlates: A Geometric Network Approach.
    Pouryahya M; Oh JH; Mathews JC; Deasy JO; Tannenbaum AR
    Sci Rep; 2018 Apr; 8(1):6402. PubMed ID: 29686393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
    Haagensen EJ; Thomas HD; Mudd C; Tsonou E; Wiggins CM; Maxwell RJ; Moore JD; Newell DR
    Eur J Cancer; 2016 Mar; 56():69-76. PubMed ID: 26820797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines.
    Wang K; Shrestha R; Wyatt AW; Reddy A; Lehár J; Wang Y; Lapuk A; Collins CC
    PLoS One; 2014; 9(7):e103050. PubMed ID: 25036042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Network as a Biomarker: A Novel Network-Based Sparse Bayesian Machine for Pathway-Driven Drug Response Prediction.
    Liu Q; Muglia LJ; Huang LF
    Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31405013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway.
    Liu H; Li X; Duan Y; Xie JB; Piao XL
    J Ethnopharmacol; 2021 May; 271():113907. PubMed ID: 33556477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.